A red eye can be a rheumatology clue
For patients and clinicians, acute eye inflammation is not a side issue when back pain, psoriasis, inflammatory bowel disease, or peripheral arthritis is also present. An episode of uveitis can be the first visible sign of spondyloarthritis, and missing that connection may delay treatment that protects vision and joints.
Uveitis means inflammation inside the uveal tract, but in rheumatology the key pattern is usually acute anterior uveitis: a painful, red, light-sensitive eye, often one-sided, sometimes recurrent. It deserves ophthalmology assessment because redness alone cannot distinguish uveitis from conjunctivitis, keratitis, scleritis, or infection. The rheumatology question is different: what immune disease is the eye revealing?
Why uveitis points toward spondyloarthritis
The strongest arthritis signal is not rheumatoid arthritis; it is the spondyloarthritis family, including ankylosing spondylitis, nonradiographic axial spondyloarthritis, psoriatic arthritis, reactive arthritis, and arthritis associated with inflammatory bowel disease.
Population studies consistently show that anterior uveitis is the most common extra-articular manifestation of axial spondyloarthritis. The ASAS-EULAR management recommendations for axial spondyloarthritis emphasize identifying extra-musculoskeletal disease because it changes biologic selection. Similarly, the 2019 ACR/Spondylitis Association of America/SPARTAN recommendations favor tumor necrosis factor inhibitor monoclonal antibodies over etanercept when recurrent uveitis is prominent, because monoclonal TNF blockade has better evidence for preventing ocular flares.
Mechanistically, this makes sense. Many spondyloarthritis pathways involve HLA-B27 biology, entheseal inflammation, interleukin-17 and interleukin-23 signaling, and TNF-driven tissue inflammation. The eye, sacroiliac joints, entheses, bowel, and skin can participate in the same immune network, even when symptoms appear years apart.
The clinical pattern that should trigger referral
A practical scenario: a 32-year-old man has his second episode of unilateral painful red eye in 18 months. He also reports morning low-back stiffness that improves after a hot shower and movement, heel pain after rest, and a sibling with psoriasis. His rheumatoid factor is negative, and an urgent-care antibiotic drop did little. That history should raise suspicion for axial spondyloarthritis far more than for a routine “red eye.”
Referral clues include:
- Recurrent acute anterior uveitis, especially unilateral and alternating between eyes.
- Inflammatory back pain beginning before age 45, improving with exercise rather than rest.
- Enthesitis, such as Achilles or plantar fascia pain, or dactylitis, the “sausage digit.”
- Personal or family history of psoriasis, inflammatory bowel disease, or known HLA-B27-associated disease.
- Elevated C-reactive protein, sacroiliitis on imaging, or strong response to NSAIDs.
HLA-B27 testing can be useful, but it is not a diagnosis. Many HLA-B27-positive people never develop disease, and some patients with spondyloarthritis are HLA-B27 negative. The test is most informative when the pretest probability is already shaped by history, examination, and imaging.
Treatment decisions depend on the eye, the joints, and the pattern
Ophthalmologists usually manage an acute anterior uveitis flare with topical corticosteroids and cycloplegic drops, while monitoring eye pressure and complications. Rheumatology enters when attacks recur, systemic inflammation is active, or steroid exposure becomes frequent. The goal is not simply to suppress one flare; it is to reduce the inflammatory tendency driving repeated organ involvement.
In axial spondyloarthritis, nonsteroidal anti-inflammatory drugs may help spinal symptoms, but they do not reliably prevent uveitis. Conventional disease-modifying antirheumatic drugs such as methotrexate or sulfasalazine have limited value for axial disease, although they may help peripheral arthritis in selected patients. When biologic therapy is appropriate, monoclonal TNF inhibitors such as adalimumab or infliximab have the strongest track record for recurrent anterior uveitis. The VISUAL I and VISUAL II trials also established adalimumab benefit in noninfectious intermediate, posterior, and panuveitis, supporting its ocular anti-inflammatory role beyond joint disease.
Treatment choice becomes more nuanced when psoriasis or bowel disease dominates. IL-17 inhibitors can be very effective for axial and psoriatic disease but have not shown the same protective effect for uveitis, and they may aggravate inflammatory bowel disease in some patients. JAK inhibitors are being studied and used across inflammatory arthritides, but ocular indications and long-term positioning remain more specific and evolving.
Common misconception: if the eye improves, the arthritis question is over
A common point of confusion is assuming that a uveitis flare that responds to eye drops was isolated. Topical therapy can quiet the eye while the systemic pattern remains unrecognized. Conversely, not every uveitis patient needs a rheumatologic label. The distinction depends on recurrence, associated symptoms, objective inflammation, and ophthalmologic classification.
Another misconception is that a negative rheumatoid factor or anti-CCP antibody rules out inflammatory arthritis. Those tests are central in suspected rheumatoid arthritis, but spondyloarthritis is usually seronegative. The more relevant questions are about inflammatory back pain, enthesitis, psoriasis, bowel symptoms, family history, HLA-B27 status, and sacroiliac imaging.
Where the evidence leaves us
Current evidence supports a deliberate approach: confirm the anatomic type of uveitis, look for spondyloarthritis features, and choose systemic therapy according to the organs involved. The strongest data favor monoclonal TNF inhibitors when recurrent anterior uveitis and axial disease intersect, while other pathways may be better for skin or peripheral joint priorities. Uncertainty remains around optimal sequencing, how early to escalate after a first ocular event, and how best to integrate newer targeted therapies. The important clinical lesson is stable: eye inflammation can be a clue to systemic immune disease, but it becomes useful only when ophthalmology and rheumatology interpret the pattern together for each patient.
Medically reviewed by Dr. Adam Elisha, DO, board-certified rheumatologist in Duluth, MN.